Tenatoprazole

Tenatoprazole

245px
Systematic (IUPAC) name
5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-imidazo[4,5-b]pyridine
Clinical data
Routes of administration	Oral
Pharmacokinetic data
Metabolism	Hepatic (CYP2C19-mediated)
Biological half-life	4.8 to 7.7 hours
Identifiers
CAS Number	113712-98-4 Y
ATC code	none
PubChem	CID: 636411
ChemSpider	552196 Y
UNII	RE0689TX2K Y
Chemical data
Formula	C16H18N4O3S
Molecular mass	346.405 g/mol
SMILES O=S(c2nc1nc(OC)ccc1n2)Cc3ncc(c(OC)c3C)C
InChI InChI=1S/C16H18N4O3S/c1-9-7-17-12(10(2)14(9)23-4)8-24(21)16-18-11-5-6-13(22-3)19-15(11)20-16/h5-7H,8H2,1-4H3,(H,18,19,20) Y Key:ZBFDAUIVDSSISP-UHFFFAOYSA-N Y
(verify)

Tenatoprazole is a proton pump inhibitor drug candidate that was undergoing clinical testing as a potential treatment for reflux oesophagitis and peptic ulcer as far back as 2003. The compound was invented by Mitsubishi Tanabe Pharma and was licensed to Negma Laboratories (part of Wockhardt as of 2007).

Mitsubishi reported that tenatoprazole was still in Phase I clinical trials in 2007 and again in 2012.

Tenatoprazole has an imidazopyridine ring in place of the benzimidazole moiety found in other proton pump inhibitors, and has a half-life about seven times longer than other PPIs.

See also

• Imidazopyridine